IBDEI03Z ; ; 01-MAY-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 01, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9529,0)
 ;;=C92.41^^48^488^19
 ;;^UTILITY(U,$J,358.3,9529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9529,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,9529,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,9529,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,9530,0)
 ;;=C92.40^^48^488^20
 ;;^UTILITY(U,$J,358.3,9530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9530,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,9530,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,9530,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,9531,0)
 ;;=D56.0^^48^488^21
 ;;^UTILITY(U,$J,358.3,9531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9531,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,9531,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,9531,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,9532,0)
 ;;=D63.1^^48^488^23
 ;;^UTILITY(U,$J,358.3,9532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9532,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,9532,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,9532,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,9533,0)
 ;;=D63.0^^48^488^24
 ;;^UTILITY(U,$J,358.3,9533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9533,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,9533,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,9533,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,9534,0)
 ;;=D63.8^^48^488^22
 ;;^UTILITY(U,$J,358.3,9534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9534,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,9534,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,9534,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,9535,0)
 ;;=C22.3^^48^488^27
 ;;^UTILITY(U,$J,358.3,9535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9535,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,9535,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,9535,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,9536,0)
 ;;=D61.9^^48^488^28
 ;;^UTILITY(U,$J,358.3,9536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9536,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,9536,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,9536,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,9537,0)
 ;;=D56.1^^48^488^30
 ;;^UTILITY(U,$J,358.3,9537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9537,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,9537,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,9537,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,9538,0)
 ;;=C83.79^^48^488^32
 ;;^UTILITY(U,$J,358.3,9538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9538,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,9538,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,9538,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,9539,0)
 ;;=C83.70^^48^488^33
 ;;^UTILITY(U,$J,358.3,9539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9539,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,9539,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,9539,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,9540,0)
 ;;=D09.0^^48^488^40
 ;;^UTILITY(U,$J,358.3,9540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9540,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,9540,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,9540,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,9541,0)
 ;;=D06.9^^48^488^41
 ;;^UTILITY(U,$J,358.3,9541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9541,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,9541,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,9541,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,9542,0)
 ;;=D06.0^^48^488^43
 ;;^UTILITY(U,$J,358.3,9542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9542,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,9542,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,9542,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,9543,0)
 ;;=D06.1^^48^488^44
 ;;^UTILITY(U,$J,358.3,9543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9543,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,9543,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,9543,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,9544,0)
 ;;=D06.7^^48^488^42
 ;;^UTILITY(U,$J,358.3,9544,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9544,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,9544,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,9544,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,9545,0)
 ;;=D04.9^^48^488^45
 ;;^UTILITY(U,$J,358.3,9545,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9545,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,9545,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,9545,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,9546,0)
 ;;=C91.11^^48^488^48
 ;;^UTILITY(U,$J,358.3,9546,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9546,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,9546,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,9546,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,9547,0)
 ;;=C91.10^^48^488^49
 ;;^UTILITY(U,$J,358.3,9547,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9547,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,9547,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,9547,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,9548,0)
 ;;=C92.11^^48^488^50
 ;;^UTILITY(U,$J,358.3,9548,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9548,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,9548,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,9548,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,9549,0)
 ;;=C92.10^^48^488^51
 ;;^UTILITY(U,$J,358.3,9549,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9549,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,9549,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,9549,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,9550,0)
 ;;=D47.1^^48^488^52
 ;;^UTILITY(U,$J,358.3,9550,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9550,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,9550,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,9550,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,9551,0)
 ;;=C82.69^^48^488^53
 ;;^UTILITY(U,$J,358.3,9551,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9551,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,9551,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,9551,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,9552,0)
 ;;=C82.60^^48^488^54
 ;;^UTILITY(U,$J,358.3,9552,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9552,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,9552,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,9552,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,9553,0)
 ;;=D56.2^^48^488^55
 ;;^UTILITY(U,$J,358.3,9553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9553,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,9553,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,9553,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,9554,0)
 ;;=D75.9^^48^488^56
 ;;^UTILITY(U,$J,358.3,9554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9554,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,9554,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,9554,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,9555,0)
 ;;=D59.0^^48^488^59
 ;;^UTILITY(U,$J,358.3,9555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9555,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,9555,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,9555,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,9556,0)
 ;;=D59.2^^48^488^60
 ;;^UTILITY(U,$J,358.3,9556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9556,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,9556,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,9556,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,9557,0)
 ;;=R59.9^^48^488^63
 ;;^UTILITY(U,$J,358.3,9557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9557,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,9557,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,9557,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,9558,0)
 ;;=D47.3^^48^488^64
 ;;^UTILITY(U,$J,358.3,9558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9558,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,9558,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,9558,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,9559,0)
 ;;=C82.09^^48^488^65
 ;;^UTILITY(U,$J,358.3,9559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9559,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,9559,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,9559,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,9560,0)
 ;;=C82.00^^48^488^66
 ;;^UTILITY(U,$J,358.3,9560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9560,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,9560,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,9560,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,9561,0)
 ;;=C82.19^^48^488^67
 ;;^UTILITY(U,$J,358.3,9561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9561,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,9561,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,9561,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,9562,0)
 ;;=C82.10^^48^488^68
 ;;^UTILITY(U,$J,358.3,9562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9562,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,9562,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,9562,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,9563,0)
 ;;=C82.29^^48^488^69
 ;;^UTILITY(U,$J,358.3,9563,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9563,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,9563,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,9563,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,9564,0)
 ;;=C82.20^^48^488^70
 ;;^UTILITY(U,$J,358.3,9564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9564,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,9564,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,9564,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,9565,0)
 ;;=C82.39^^48^488^71
 ;;^UTILITY(U,$J,358.3,9565,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9565,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,9565,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,9565,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,9566,0)
 ;;=C82.30^^48^488^72
 ;;^UTILITY(U,$J,358.3,9566,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9566,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,9566,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,9566,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,9567,0)
 ;;=C82.49^^48^488^73
 ;;^UTILITY(U,$J,358.3,9567,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9567,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,9567,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,9567,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,9568,0)
 ;;=C82.40^^48^488^74
 ;;^UTILITY(U,$J,358.3,9568,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9568,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,9568,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,9568,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,9569,0)
 ;;=C82.99^^48^488^75
 ;;^UTILITY(U,$J,358.3,9569,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9569,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,9569,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,9569,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,9570,0)
 ;;=C82.90^^48^488^76
 ;;^UTILITY(U,$J,358.3,9570,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9570,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,9570,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,9570,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,9571,0)
 ;;=R59.1^^48^488^61
 ;;^UTILITY(U,$J,358.3,9571,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9571,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,9571,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,9571,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,9572,0)
 ;;=C91.40^^48^488^80
 ;;^UTILITY(U,$J,358.3,9572,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9572,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,9572,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,9572,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,9573,0)
 ;;=C91.42^^48^488^78
 ;;^UTILITY(U,$J,358.3,9573,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9573,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,9573,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,9573,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,9574,0)
 ;;=C91.41^^48^488^79
 ;;^UTILITY(U,$J,358.3,9574,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9574,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,9574,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,9574,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,9575,0)
 ;;=D57.01^^48^488^81
 ;;^UTILITY(U,$J,358.3,9575,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9575,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,9575,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,9575,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,9576,0)
 ;;=D57.00^^48^488^82
 ;;^UTILITY(U,$J,358.3,9576,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9576,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,9576,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,9576,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,9577,0)
 ;;=D57.02^^48^488^83
 ;;^UTILITY(U,$J,358.3,9577,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9577,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,9577,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,9577,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,9578,0)
 ;;=D68.32^^48^488^85
 ;;^UTILITY(U,$J,358.3,9578,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9578,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,9578,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,9578,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,9579,0)
 ;;=C22.2^^48^488^86
 ;;^UTILITY(U,$J,358.3,9579,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9579,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,9579,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,9579,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,9580,0)
 ;;=D58.9^^48^488^88
 ;;^UTILITY(U,$J,358.3,9580,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9580,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,9580,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,9580,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,9581,0)
 ;;=C81.99^^48^488^89
 ;;^UTILITY(U,$J,358.3,9581,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9581,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,9581,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,9581,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,9582,0)
 ;;=C81.90^^48^488^90
 ;;^UTILITY(U,$J,358.3,9582,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9582,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,9582,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,9582,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,9583,0)
 ;;=D89.2^^48^488^91
 ;;^UTILITY(U,$J,358.3,9583,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9583,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,9583,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,9583,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,9584,0)
 ;;=D05.12^^48^488^94
 ;;^UTILITY(U,$J,358.3,9584,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9584,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,9584,1,4,0)
 ;;=4^D05.12
 ;;^UTILITY(U,$J,358.3,9584,2)
 ;;=^5001931
 ;;^UTILITY(U,$J,358.3,9585,0)
 ;;=D05.11^^48^488^95
 ;;^UTILITY(U,$J,358.3,9585,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9585,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,9585,1,4,0)
 ;;=4^D05.11
 ;;^UTILITY(U,$J,358.3,9585,2)
 ;;=^5001930
 ;;^UTILITY(U,$J,358.3,9586,0)
 ;;=D05.10^^48^488^96
 ;;^UTILITY(U,$J,358.3,9586,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9586,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,9586,1,4,0)
 ;;=4^D05.10
 ;;^UTILITY(U,$J,358.3,9586,2)
 ;;=^5001929
 ;;^UTILITY(U,$J,358.3,9587,0)
 ;;=D50.0^^48^488^97
 ;;^UTILITY(U,$J,358.3,9587,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9587,1,3,0)
 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
 ;;^UTILITY(U,$J,358.3,9587,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,9587,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,9588,0)
 ;;=D50.9^^48^488^98
 ;;^UTILITY(U,$J,358.3,9588,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9588,1,3,0)
 ;;=3^Iron Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,9588,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,9588,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,9589,0)
 ;;=C46.9^^48^488^99
 ;;^UTILITY(U,$J,358.3,9589,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9589,1,3,0)
 ;;=3^Kaposi's Sarcoma,Unspec
 ;;^UTILITY(U,$J,358.3,9589,1,4,0)
 ;;=4^C46.9
 ;;^UTILITY(U,$J,358.3,9589,2)
 ;;=^5001108
 ;;^UTILITY(U,$J,358.3,9590,0)
 ;;=C22.0^^48^488^100
 ;;^UTILITY(U,$J,358.3,9590,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9590,1,3,0)
 ;;=3^Liver Cell Carcinoma
 ;;^UTILITY(U,$J,358.3,9590,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,9590,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,9591,0)
 ;;=D05.02^^48^488^101
 ;;^UTILITY(U,$J,358.3,9591,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9591,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,9591,1,4,0)
 ;;=4^D05.02
 ;;^UTILITY(U,$J,358.3,9591,2)
 ;;=^5001928
 ;;^UTILITY(U,$J,358.3,9592,0)
 ;;=D05.01^^48^488^102
 ;;^UTILITY(U,$J,358.3,9592,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9592,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,9592,1,4,0)
 ;;=4^D05.01
 ;;^UTILITY(U,$J,358.3,9592,2)
 ;;=^5001927
 ;;^UTILITY(U,$J,358.3,9593,0)
 ;;=D05.00^^48^488^103
 ;;^UTILITY(U,$J,358.3,9593,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9593,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,9593,1,4,0)
 ;;=4^D05.00
 ;;^UTILITY(U,$J,358.3,9593,2)
 ;;=^5001926
 ;;^UTILITY(U,$J,358.3,9594,0)
 ;;=R59.0^^48^488^62
 ;;^UTILITY(U,$J,358.3,9594,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9594,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Localized
 ;;^UTILITY(U,$J,358.3,9594,1,4,0)
 ;;=4^R59.0
 ;;^UTILITY(U,$J,358.3,9594,2)
 ;;=^5019529
 ;;^UTILITY(U,$J,358.3,9595,0)
 ;;=C83.59^^48^488^104
 ;;^UTILITY(U,$J,358.3,9595,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9595,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,9595,1,4,0)
 ;;=4^C83.59
 ;;^UTILITY(U,$J,358.3,9595,2)
 ;;=^5001590
 ;;^UTILITY(U,$J,358.3,9596,0)
 ;;=C83.50^^48^488^105
 ;;^UTILITY(U,$J,358.3,9596,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9596,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,9596,1,4,0)
 ;;=4^C83.50
 ;;^UTILITY(U,$J,358.3,9596,2)
 ;;=^5001581
 ;;^UTILITY(U,$J,358.3,9597,0)
 ;;=C43.9^^48^488^108
 ;;^UTILITY(U,$J,358.3,9597,1,0)
 ;;=^358.31IA^4^2
